Seres Therapeutics (NASDAQ:MCRB) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a research report sent to investors on Tuesday.

Several other research firms have also issued reports on MCRB. Chardan Capital reiterated a “buy” rating and set a $1.25 price objective on shares of Seres Therapeutics in a research note on Wednesday, November 13th. Canaccord Genuity Group reiterated a “buy” rating and set a $10.00 price objective on shares of Seres Therapeutics in a research note on Thursday, November 14th. Finally, JPMorgan Chase & Co. lowered Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Price Performance

Shares of MCRB stock opened at $0.77 on Tuesday. The stock has a market cap of $131.23 million, a P/E ratio of -3.28 and a beta of 2.06. Seres Therapeutics has a one year low of $0.54 and a one year high of $2.05. The stock has a fifty day moving average price of $0.82 and a 200 day moving average price of $0.91.

Institutional Trading of Seres Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in MCRB. Vanguard Group Inc. increased its stake in shares of Seres Therapeutics by 12.1% in the first quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company’s stock valued at $5,213,000 after buying an additional 729,514 shares in the last quarter. Virtu Financial LLC acquired a new stake in Seres Therapeutics in the first quarter worth about $73,000. Providence Wealth Advisors LLC increased its position in Seres Therapeutics by 49.5% in the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 25,250 shares during the period. Point72 DIFC Ltd acquired a new stake in Seres Therapeutics in the second quarter worth about $64,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Seres Therapeutics in the second quarter worth about $92,000. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.